Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome Clinical Trial

Official title:

Effects of Low FODMAP Diet on Colonic Epithelial Physiology in Diarrhea-predominant Irritable Bowel Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04542018
• Other study ID #: HUM00166423
• Secondary ID: K23DK129327
• Status: Completed
• Phase: N/A
• Start date: August 3, 2020
• Est. completion date: May 15, 2024

Study information

• Verified date: May 2024
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research is studying whether changing an individual's diet may have an impact as a treatment or outcome for Irritable Bowel Syndrome (IBS). This research will show if diet might play a role in triggering changes that may cause IBS. This study is being done to learn if a low FODMAP (fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols) diet causes changes in the colon lining which mediates improvement in IBS symptoms.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: May 15, 2024
• Est. primary completion date: May 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Normal serum studies including serum tissue-transglutaminase antibodies, thyroid stimulating hormone levels, C-reactive protein or fecal calprotectin, complete blood count since the onset of symptoms.

• Normal stool studies including, ova and parasites since the onset of symptoms

• IBS-SSS score of =175 at the end of the 7-day screening period

In case of presence of any alarm features and/or elevated inflammatory markers (C-reactive protein or fecal calprotectin), patients will be eligible if they have been excluded for inflammatory bowel disease with colonoscopy in the last one year.

Exclusion criteria

• individuals already on a LFD or other dietary restriction such as gluten free diet within the past 6 months

• individuals with any known food allergy or insulin-dependent diabetes

• known history of celiac disease, inflammatory bowel disease or microscopic colitis

• prior small bowel or colonic surgery or cholecystectomy

• pregnant patients

• Antibiotics in the past 3 months

• Those who regularly use mast cell stabilizers or anti-histaminic or non-steroidal anti-inflammatory agents (NSAIDs) excluding daily baby aspirin or steroids or bile-acid binder.

Related Conditions & MeSH terms

• Diarrhea
• Irritable Bowel Syndrome
• Syndrome

Intervention

Other:
• a low FODMAP diet for 4 weeks
low FODMAP diet for 4 weeks

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
University of Michigan	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Lactulose Mannitol excretion	Changes in cumulative excretion of lactulose and mannitol in timed urine collection before and after low FODMAP diet	4 weeks
Secondary	Changes in epithelial permeability	Changes in tight junction gene expression, immunostaining of tight junctions in colonic biopsies before and after low FODMAP diet	4 weeks
Secondary	Changes in stool microbiome	Changes in relative abundance of bacteria before and after low FODMAP diet	4 weeks